Galmed Pharmaceuticals (GLMD) Retained Earnings (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Retained Earnings of -$383000.0 for Q1 2026, up 3.53% year-over-year from -$369953.8 in Q1 2025, and down 26.4% quarter-over-quarter from -$303000.0 in Q4 2025.
Galmed Pharmaceuticals (GLMD) Retained Earnings (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Retained Earnings history runs 14 years deep, the most recent figure standing at -$383000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 3.53% year-over-year to -$383000.0; the TTM figure through Mar 2026 stood at -$383000.0 (up 3.53% YoY), while the FY2025 annual figure was -$303000.0, up 98.2% from the prior year.
- Retained Earnings for Q1 2026 stood at -$383000.0, down from -$303000.0 in the prior quarter.
- The five-year high for Retained Earnings was $207.1 million in Q4 2023, with the low at -$16.8 million in Q4 2024.
- The 5-year median for Retained Earnings is -$435000.0 (2024), against an average of $22.3 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings surged 99.57% in 2022, then tumbled 558.44% in 2023.
- Galmed Pharmaceuticals' Retained Earnings stood at $200.1 million in 2022, then grew by 3.47% to $207.1 million in 2023, then sank by 108.13% to -$16.8 million in 2024, then jumped by 98.2% to -$303000.0 in 2025, then decreased by 26.4% to -$383000.0 in 2026.
- Business Quant data shows GLMD's Retained Earnings at -$383000.0 in Q1 2026, -$303000.0 in Q4 2025, and -$316000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | 223.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -383,000.00 |
| Dec 31, 2025 | -303,000.00 |
| Sep 30, 2025 | -316,000.00 |
| Jun 30, 2025 | -403,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Dec 31, 2024 | -16.84 Mn |
| Sep 30, 2024 | -342,000.00 |
| Jun 30, 2024 | -435,000.00 |
| Mar 31, 2024 | -455,000.00 |
| Dec 31, 2023 | 207.08 Mn |
| Sep 30, 2023 | -607,000.00 |
| Jun 30, 2023 | -662,000.00 |
| Mar 31, 2023 | -4.06 Mn |
| Dec 31, 2022 | 200.14 Mn |
| Sep 30, 2022 | -876,000.00 |
| Jun 30, 2022 | -982,000.00 |
| Mar 31, 2022 | -616,000.00 |
| Dec 31, 2021 | 198.77 Mn |
| Sep 30, 2021 | -160.72 Mn |
| Jun 30, 2021 | -153.01 Mn |